(R)-Filanesib
≥98%
- Product Code: 99221
CAS:
885060-08-2
| Molecular Weight: | 420.48 g./mol | Molecular Formula: | C₂₀H₂₂F₂N₄O₂S |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8℃ |
Product Description:
(R)-Filanesib is primarily investigated for its potential in cancer therapy, particularly in the treatment of multiple myeloma. It functions as a selective inhibitor of kinesin spindle protein (KSP), which is essential for cell division. By inhibiting KSP, it disrupts the formation of the mitotic spindle, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. Its (R)-enantiomer is specifically studied due to its enhanced potency and reduced off-target effects compared to its counterpart. Clinical trials have explored its efficacy as a monotherapy or in combination with other chemotherapeutic agents, aiming to improve outcomes for patients with relapsed or refractory multiple myeloma. Research continues to evaluate its safety profile and therapeutic potential in other malignancies.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | $415.42 |
+
-
|
| 0.010 | 10-20 days | $670.37 |
+
-
|
(R)-Filanesib
(R)-Filanesib is primarily investigated for its potential in cancer therapy, particularly in the treatment of multiple myeloma. It functions as a selective inhibitor of kinesin spindle protein (KSP), which is essential for cell division. By inhibiting KSP, it disrupts the formation of the mitotic spindle, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. Its (R)-enantiomer is specifically studied due to its enhanced potency and reduced off-target effects compared to its counterpart. Clinical trials have explored its efficacy as a monotherapy or in combination with other chemotherapeutic agents, aiming to improve outcomes for patients with relapsed or refractory multiple myeloma. Research continues to evaluate its safety profile and therapeutic potential in other malignancies.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :